No Data
The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus
① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.
Trending Industry Today: CARSGEN-B Leads Gains In Pharmaceutical Companies Stocks
Individual Investors Who Hold 45% of Peijia Medical Limited (HKG:9996) Gained 18%, Institutions Profited as Well
Peijia Medical Sees Up to 43% Jump in 2024 Revenue
PEIJIA-B (09996.HK) expected revenue for 2024 is approximately 0.61 billion yuan to -0.63 billion yuan, a year-on-year growth of about 38.3%-42.8%.
Gelonghui reported on February 10 that PEIJIA-B (09996.HK) announced that for the year ending December 31, 2024, the company's revenue is expected to be approximately 0.61 billion to 0.63 billion yuan, representing a year-on-year growth of about 38.3% to 42.8%. The strong revenue growth is mainly attributed to: (i) the continuous rapid growth of all neurointerventional product lines of the group; and (ii) the group's expanded market share in China's transcatheter aortic valve replacement ("TAVR") market. During the reporting period, the increase in surgical penetration rates, winning bids in volume-based procurement, and its comprehensive product pipeline and effective marketing contributed significantly.
Express News | Peijia Medical Sees FY Revenue Between RMB610.0 Mln and RMB630.0 Mln
Peijia Medical Limited's (HKG:9996) 29% Share Price Plunge Could Signal Some Risk
